D. E. Shaw & Co., Inc. Ascendis Pharma A/S Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 5,000 shares of ASND stock, worth $779,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,000

Previous 90,380 94.47%

Holding current value

$779,300

Previous $13.5 Million 94.9%

% of portfolio

0.0%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$122.0 - $146.6 $6.39 Million - $7.68 Million	-52,400 Reduced 57.98%	37,980 $5.23 Million
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $21.6 Million - $29.3 Million	-191,157 Reduced 67.9%	90,380 $13.5 Million
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $7.09 Million - $9 Million	-58,581 Reduced 17.22%	281,537 $38.4 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $9.25 Million - $11.9 Million	74,961 Added 28.27%	340,118 $51.4 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $3.84 Million - $5.68 Million	44,604 Added 20.22%	265,157 $33.4 Million
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $7.65 Million - $9.2 Million	88,470 Added 66.98%	220,553 $20.7 Million
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $499,024 - $697,892	-7,133 Reduced 5.12%	132,083 $11.8 Million
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $2.36 Million - $2.85 Million	22,512 Added 19.29%	139,216 $14.9 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $2.47 Million - $3.29 Million	24,894 Added 27.11%	116,704 $14.3 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $669,887 - $878,753	-7,972 Reduced 7.99%	91,810 $9.48 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $4.07 Million - $6.14 Million	-52,177 Reduced 34.34%	99,782 $9.28 Million
Q1 2022 May 16, 2022	SELL	$102.18 - $135.75 $271,900 - $361,230	-2,661 Reduced 1.72%	151,959 $17.8 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $16.5 Million - $22 Million	129,793 Added 522.79%	154,620 $20.8 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $2.11 Million - $3.31 Million	18,710 Added 305.87%	24,827 $3.96 Million
Q2 2021 Aug 16, 2021	SELL	$121.62 - $145.29 $273,645 - $326,902	-2,250 Reduced 26.89%	6,117 $805,000
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $1.78 Million - $2.47 Million	-14,241 Reduced 62.99%	8,367 $1.08 Million
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $943,941 - $1.14 Million	6,243 Added 38.15%	22,608 $3.77 Million
Q3 2020 Nov 16, 2020	SELL	$134.29 - $154.32 $507,750 - $583,483	-3,781 Reduced 18.77%	16,365 $2.53 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $16,297 - $22,933	147 Added 0.74%	20,146 $2.98 Million
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $1.72 Million - $2.58 Million	17,750 Added 789.24%	19,999 $2.25 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $1.15 Million - $1.75 Million	-12,573 Reduced 84.83%	2,249 $313,000
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $207,215 - $257,180	-2,163 Reduced 12.73%	14,822 $1.43 Million
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $25.8 Million - $31.9 Million	-241,192 Reduced 93.42%	16,985 $1.96 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $13.2 Million - $27.6 Million	211,996 Added 459.05%	258,177 $30.4 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $324,395 - $409,729	5,881 Added 14.59%	46,181 $2.89 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $1.3 Million - $1.55 Million	20,377 Added 102.28%	40,300 $2.86 Million
Q2 2018 Aug 14, 2018	BUY	$58.55 - $73.92 $842,007 - $1.06 Million	14,381 Added 259.49%	19,923 $1.33 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $216,027 - $377,077	5,542 New	5,542 $362,000

Others Institutions Holding ASND

# of Institutions

236

Shares Held

60.2M

Call Options Held

80.3K

Put Options Held

216K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.7B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account